Chronic Idiopathic Urticaria:

Slides:

Advertisements

Similar presentations

The ins and outs of Hives- with apologies to bees!

Advertisements

H1-antihistamines for chronic spontaneous urticaria KHOA NỘI 2 BS NGUYỄN THÚC BỘI NGỌC.

A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo.

Purpose To determine whether metoprolol controlled/extended release

Badrul A. Chowdhury, MD, PhD

Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:

Chronic Urticaria: New Management Options FACULTY NAME.

Anti-IgE: Beyond Asthma Michael S. Blaiss, MD Clinical Professor of Pediatrics and Medicine University of Tennessee Health Science Center Memphis, Tennessee.

Summary of Issues on Urticaria as an OTC Indication Charles Ganley, M.D. Division of OTC Drug Products April 22, 2002 Non-Prescription Drug Advisory Committee.

C-BR- 1 Raptiva ™ (efalizumab) Benefit:Risk Assessment Charles Johnson, MB, ChB Senior Director Head of Specialty Biotherapeutics Genentech, Inc.

CLINICAL EFFICACY TESTING for NASAL DRUGS Mary M. Fanning, M.D., Ph.D. Associate Director for Medical Affairs Office of Generic Drugs, FDA June 4, 1999.

Chronic Urticaria & Angioedema successfully treated by Thyroxin Thaer Douri, M.D, Dermatologist, Hama - Syria.

 Design Randomisation* 2 : 1 Double blind *Randomisation was stratified on genotype (1a vs 1b) and ILB28 genotype (CC or non-CC) N = 134 N = 257 W24W48.

Jonathan Wilkin, M.D. Director, Division of Dermatologic and Dental Drug Products, FDA URTICARIA: Overview and OTC Considerations April 22, 2002.

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised,placebo-controlled.

Joint Non-Prescription Drugs and Pediatric Advisory Committee Meeting October 18-19, 2007 Considerations for Extrapolation of Efficacy from Adults to Children.

Chronic Idiopathic Urticaria:

Opiate Therapy in Chronic Cough Alyn H. Morice, Madhav S. Menon, Siobhan A. Mulrennan, Caroline F. Everett, Caroline Wright, Jennifer Jackson and Rachel.

Copyright © 2003 American Medical Association. All rights reserved.

Nymox Pivotal Phase 3 Fexapotide (NX-1207) BPH Extension Trial Successfully Meets Primary Endpoint

Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria Matt Morgan, MD, Andrew Cooke, MD, Laura Rogers,

SHARON CHAN1, SARAH DENMAN1 & SINISA SAVIC1*

Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo David S. Baldwin, Satoshi Asakura, Tsukasa Koyama,

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.

Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma.

Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials Zuo-Tao Zhao, MD, PhD, Chun-Mei Ji, M Pharm,

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:

CHRONIC IDIOPATHIC URTICARIA

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

Thomas B. Casale, MD, Patrick H. Win, MD, Jonathan A

Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy Thomas B. Casale, MD, Jonathan A. Bernstein,

Chronic Idiopathic Urticaria

Updates on Anti-VEGF Therapy: Improving Durability and Predicting Response.

ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,

ODYSSEY FH I and II Trial design: Participants with heterozygous familial hypercholesterolemia on statin therapy were randomized to alirocumab 75 mg SQ.

Shyam Joshi, MD, David A. Khan, MD

Urticaria DR.A.Asilian.

Use of the Cumulative Proportion of Responders Analysis Graph to Present Pain Data Over a Range of Cut-Off Points: Making Clinical Trial Data More Understandable

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy Allen Kaplan, MD, Dennis Ledford,

Predicting Chronic Spontaneous Urticaria Symptom Return After Omalizumab Treatment Discontinuation: Exploratory Analysis Marta Ferrer, MD, PhD, Ana Giménez-Arnau,

Proportion of Patients Achieving a ≥30% Reduction in Pain Scores at Week 12 of Stable Dose Treatment

FX006 Pivotal Ph 2b Data September , 2015

GI clinical research 2002–2003: the year in review

Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina.

High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired.

Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria Sarbjit S. Saini, Theodore A. Omachi, Benjamin.

What's New in Therapeutic Options for Moderate to Severe RA?

Basophil FcɛRI histamine release parallels expression of Src-homology 2–containing inositol phosphatases in chronic idiopathic urticaria Becky M. Vonakis,

Treatment of chronic autoimmune urticaria with omalizumab

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria

EXPERT INSIGHTS: IL-17 INHIBITION IN PSORIASIS CARE

Omalizumab, an Anti-IgE mAb, Receives Approval for the Treatment of Chronic Idiopathic/Spontaneous Urticaria Keith C.P. Wu, Zarif K. Jabbar-Lopez Journal.

Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized,

Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria Matt Morgan, MD, Andrew Cooke, MD, Laura Rogers,

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria Janine Gericke, PhD, Martin Metz, MD, Tatevik Ohanyan,

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

Phase 3 Treatment-Naïve and Treatment-Experienced

Omalizumab improves asthma-related quality of life in patients with severe allergic asthma Albert Finn, MDa, Gary Gross, MDb, Julius van Bavel, MDc,

Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria Katja Koch, Karsten Weller, MD, Andreas Werner,

New Models of Care in Idiopathic Pulmonary Fibrosis

Expansion (Phase II, n=18)

Nathaniel P Katz, MD Journal of Pain and Symptom Management

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: A pooled analysis of the Phase 3 VOYAGE 1 and VOYAGE.

The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria Maria Staevska, MD, Todor A.

PHOENIX I: PASI 75 Response After 12 Weeks

Desloratadine: A new, nonsedating, oral antihistamine

Late-Breaking Data on LDL-C Reduction

Presentation transcript:

Chronic Idiopathic Urticaria:

Characteristics of Physical Urticarias*

Cold Urticaria

Histamine Release in Cold Urticaria

Recognized Associations With CIU

ASST

Criteria for Efficacy in Treating Chronic Urticaria

Effectiveness of Levocetirizine and Desloratadine Effectiveness of Levocetirizine and Desloratadine* Given at Up to 4 Times† Conventional Doses for Difficult-to-treat Urticaria

Cyclosporine

Omalizumab Phase 3 Clinical Studies in Patients With CIU

ASTERIA II Omalizumab 150 and 300 mg for 12 Weeks Significantly Improved UAS7 and Hives Score vs Placebo

ASTERIA II Omalizumab Increased the Proportion of Patients Who Were Well Controlled or Free of Itch and Hive

GLACIAL Significant Improvements in UAS7 at Week 12 With Sustained Benefit at Week 24

GLACIAL Omalizumab Increased the Proportion of Patients Well Controlled or Free of Itch and Hives

Therapeutic Response

Approaches to Consider When Antihistamines Fail